First Test That Can Detect COVID-19 Virus Mutations Authorized By FDA
Executive Summary
The US FDA on 10 June authorized use of Illumina’s COVIDSeq next generation sequencing diagnostic test to detect the SARS-CoV-2 virus and figure out if it’s mutating. The agency has high hopes this first-of-its-kind test will give researchers a better picture in the ongoing global fight against the COVID-19 pandemic.
You may also be interested in...
Illumina CEO deSouza: Innovation Is ‘Our North Star’
The total addressable market for genomics-based infectious disease testing has expanded in recent months, says Illumina, after becoming the first company to receive a US EUA for a next-generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego company.
Innovation Is 'Our North Star’ Says Illumina Chief
The total addressable market for genomics infectious disease testing is increasing, says Illumina, after becoming the first company to receive a US EUA for a next generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego group.
Roche And Illumina Sign 15-Year Partnership To Advance NGS Testing
Roche and Illumina have entered a 15-year, non-exclusive partnership to expand access to next-generation sequencing- based testing in cancer care.